RNF114 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Nimbolide (SCHEMBL2146198)	1.00	3/20
Nimbolide (SCHEMBL16561839)	1.00	3/20
Nimbolide (SCHEMBL21163877)	1.00	3/20
Nimbolide (SCHEMBL23483973)	1.00	3/20
Nimbolide (SCHEMBL26312156)	1.00	3/20
Nimbolide (SCHEMBL26690496)	1.00	3/20
SCHEMBL24075813	0.86	3/20
SCHEMBL24076459	0.86	3/20
SCHEMBL26698833	0.86	3/20
SCHEMBL24076795	0.86	3/20
SCHEMBL19397851	0.85	3/20
SCHEMBL24625130	0.82	3/20
SCHEMBL24075804	0.80	3/20
SCHEMBL24075812	0.80	3/20
SCHEMBL24076524	0.80	3/20
SCHEMBL24076607	0.80	3/20
SCHEMBL24076626	0.80	3/20
SCHEMBL24625481	0.78	3/20
SCHEMBL24075783	0.76	3/20
SCHEMBL24076520	0.76	3/20

Clinical trials — most relevant to RNF114 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC	EARLY_PHASE1	RECRUITING
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome	nan	ACTIVE_NOT_RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer	nan	UNKNOWN
Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer	nan	UNKNOWN
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RNF114 binder may also engage these)

Protein	Name	Similarity
Q6J212	—	1.000	Q6J212 →
Q6J1I8	—	1.000	Q6J1I8 →
Q9ET26	—	1.000	Q9ET26 →
Q4U5R4	—	1.000	Q4U5R4 →
Q6J2U6	—	1.000	Q6J2U6 →
Q1L721	—	0.993	Q1L721 →
Q96EQ8	—	0.992	Q96EQ8 →
Q95KF1	—	0.988	Q95KF1 →
Q8T3Y0	—	0.987	Q8T3Y0 →
KAT8	Histone acetyltransferase KAT8	0.985	landscape →
Q4R5T4	—	0.985	Q4R5T4 →
Q6ZPS6	—	0.985	Q6ZPS6 →
Q9D9R0	—	0.985	Q9D9R0 →
KDM5B	Lysine-specific demethylase 5B	0.984	landscape →
O76924	—	0.984	O76924 →
Q91ZY8	—	0.984	Q91ZY8 →
Q5XI06	—	0.984	Q5XI06 →
Q8I147	—	0.983	Q8I147 →
O60260	—	0.983	O60260 →
D3ZEY4	—	0.983	D3ZEY4 →
Q9H0A6	—	0.983	Q9H0A6 →
D3YY23	—	0.983	D3YY23 →
F1RB95	—	0.983	F1RB95 →
M9MRI4	—	0.983	M9MRI4 →
Q5F3R2	—	0.983	Q5F3R2 →
Q7ZW16	—	0.983	Q7ZW16 →
Q1L8G6	—	0.983	Q1L8G6 →
Q6GLD9	—	0.982	Q6GLD9 →
Q9UDW3	—	0.982	Q9UDW3 →
Q8BGX0	—	0.982	Q8BGX0 →